Intranasal esketamine gets FDA support for refractory depression

FDA panels are backing intranasal esketamine for refractory depression. Also today, the office of the National Coordinator of Health Information Technology aims to help doctors and patients with information sharing, most physicians think that health care costs and access are unlikely to improve in 2019, and vaccination and antiviral treatment do not affect the risk of stroke following shingles.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify